{"id":113744,"date":"2026-06-22T11:56:22","date_gmt":"2026-06-22T11:56:22","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/113744\/"},"modified":"2026-06-22T11:56:22","modified_gmt":"2026-06-22T11:56:22","slug":"south-africa-court-bars-idexis-from-selling-compounded-ozempic-in-novo-nordisk-case-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/113744\/","title":{"rendered":"South Africa court bars iDexis from selling compounded Ozempic in Novo Nordisk case"},"content":{"rendered":"<p>South \u200bAfrica&#8217;s High \u200cCourt has granted \u200bNovo Nordisk an interim interdict barring a \u200clocal pharmacy group from manufacturing and selling compounded weight-loss medicines containing semaglutide, in \u200ca ruling that shows tightening scrutiny \u200cof unregistered drugs.<\/p>\n<p>The Gauteng Division of the High Court in Pretoria ruled \u2060on Monday \u200bthat \u2060iDexis and its director must immediately stop compounding, \u2060supplying and marketing semaglutide-based products pending the \u200boutcome of regulatory processes and potential \u2060review proceedings. Novo Nordisk, the Danish drugmaker behind \u2060blockbuster \u200bbrands Ozempic and Wegovy, had argued that iDexis was unlawfully selling \u2060unregistered semaglutide medicines and competing in the lucrative \u2060weight-loss \u2060market without complying with South Africa&#8217;s Medicines Act. <\/p>\n<p>(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)<\/p>\n","protected":false},"excerpt":{"rendered":"South \u200bAfrica&#8217;s High \u200cCourt has granted \u200bNovo Nordisk an interim interdict barring a \u200clocal pharmacy group from manufacturing&hellip;\n","protected":false},"author":2,"featured_media":113745,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[56935,53308,56934,272,3102,56936,689,17938,1910],"class_list":["post-113744","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-gauteng","tag-idexis","tag-medicines-act","tag-novo-nordisk","tag-ozempic","tag-pretoria","tag-semaglutide","tag-south-africa","tag-wegovy"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116793637980287800","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/113744","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=113744"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/113744\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/113745"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=113744"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=113744"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=113744"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}